Video Based Directly Observed Therapy for Latent TB

June 27, 2019 updated by: Soumya Chatterjee, MD, St. Louis University

Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB

Center for Disease Control (CDC) data reveal that after years of sustained decrease, the incidence of active tuberculosis (TB) disease in the US has plateaued. Most of the cases occur when Mycobacterium tuberculosis (Mtb) reactivates replication in people who have latent tuberculosis infection (LTBI). Only 5 to 10% of subjects with LTBI develop active TB Infection over their lifetime. Current US guidelines recommend treating everyone with LTBI to stop progression to active TB. As treatment is long, only about 45-55% of patients finish treatment overall, regardless of whether the patients are at high (>10%) or low lifetime risk of reactivation. The investigator's study aims to test the efficacy of a combined approach of first determining subjects at high risk of reactivation and then treating them with a CDC approved once a week treatment regimen, directly observed by a nurse over video (video-based Directly Observed Therapy, vDOT). Ensuring treatment of the high-risk group will eventually decrease the community active TB burden.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Tuberculosis (TB) in the US: Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (Mtb), is a leading cause of mortality, killing more than a million people worldwide^1. In the United States an important recent trend has been the plateauing of the active TB disease incidence at 3.0 cases per 100,000 persons^2. Current US TB control guidelines recommend treating all subjects with LTBI to prevent progression to active TB. However, treatment is given with the antibiotic Isoniazid (INH) for 6-9 months, Rifampin and Rifabutin for 4 months or INH with Rifapentine for 3 months and as subjects with LTBI are asymptomatic, treatment default rates are understandably high (>10% on average)^3-5. It is well known that a subset of patients with LTBI have higher risk of progression to active TB. Because of the high treatment default rate, a number of these "high risk" subjects receive incomplete or no preventive therapy and contribute to the incidence of active TB cases in the US. Currently, there are no strategies being implemented to identify those at highest risk and consequently treatment approaches follow the "one size fits all" paradigm. In the investigators preliminary study done at the Saint Louis University (SLU) Infectious Diseases Clinic, the investigators used an online risk calculator (TSTin3D.com)^6 to retrospectively determine the cumulative lifetime risk of progression to active TB for adults receiving treatment for latent TB. The investigators found that current practice leads to equal rates of treatment completion i.e. 57% in the high risk for active TB disease (TBhi) group (>10% cumulative risk of progression based on medical risk factors) compared to 59% for those at lowest risk (TBlow, <10% cumulative risk of progression). It is not standard of care to use a scoring system like the TSTin3d.com to assess the risk. There are certain risk factors like having HIV or being on immunosuppression that physicians ask about but most physicians do not do a quantitative risk assessment. Treatment choices are usually based on convenience and concern for side effects but the most common regimen is daily INH for 6-9 months.

This data implies that the current "treat everyone and hope that therapy is completed" approach leads to a significant number of people in the TBhi group remaining untreated and at high risk of progression to active TB. A recent advance has been a CDC approved regimen using Isoniazid (INH) and Rifapentine given weekly as directly observed therapy (DOT) for 12 weeks (known as the 3HP regimen). This regimen has shown lower toxicity, better adherence and equivalent efficacy^7-12. INH + Rifapentine (3HP) is not currently used widely as DOT is resource intensive. The investigators hypothesize that if providers use the calculator (TSTin3d.com) to firstly determine risk and then select the once weekly DOT for the TBhi group (12 doses total); the investigators can ensure that the TBhi group completes treatment. Complete treatment of the TBhi group will have the highest impact in decreasing the community burden of TB disease. The investigators propose the first US study to prospectively test the efficacy of an approach which 1) defines the TBhi group using TSTin3d.com and 2) ensures treatment completion in the TBhi group with weekly with video-based DOT (vDOT) with 3HP. Most patients nowadays have access to a smartphone with video capabilities. A HIPAA approved video application (Zoom) is already available through the Missouri Telehealth Network and can be used by the patient to interface with the TB clinic nurse over a smartphone. The investigators approach removes the need for the patients in the TBhi group to be physically present in the TB clinic. All patients identified in the TBhi group can thus be safely provided vDOT. The investigators pilot study has important implications for improving care and patient treatment outcomes as it will identify the "high risk" subjects with latent TB using tstin3d.com (Table 1), [a validated online calculator that combines TST or interferon Gamma Release Assay (IGRA) screening results with clinical information obtained from the patient, to generate an individual's cumulative risk of developing active TB disease, up to age 80^11]. The investigators will then ensure that patients complete therapy under direct observation by a nurse using video based Directly Observed Therapy (vDOT). vDOT also eliminates the need for the patient to physically visit the clinic. All patients need is access to a smartphone with video capabilities. HIPAA approved video based applications are already available for vDOT and has already been implemented successfully.^13

All of the drug options listed are standard of care currently in the US. It is currently not standard of care to use a scoring system like tstin3d.com to assess risk. There are certain risk factors like having HIV or being on immunosuppression that physicians routinely ask about but most physicians do not do a quantitative risk assessment. Treatment choices are usually based on convenience and concern for side effects but the most common regimen is daily INH for 6 months or 9 months.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Missouri
      • Saint Louis, Missouri, United States, 63104
        • Saint Louis University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults with latent tuberculosis

Description

Inclusion Criteria:

- Age 18 years + 1 day (defined as date of birth plus one day). This age cutoff has been selected as tstin3d.com has only been validated for this age group.

Subjects must have all of the following:

  • Untreated Latent Tuberculosis Infection (LTBI), defined as positive Tuberculin skin test/QuantiFERON TB Gold test or T-spot assay done within 1 month prior to enrollment.
  • Absence of active TB disease as determined by history, physical examination, chest X-ray, (sputum smear and/or culture done as needed by the assessing physician for Mtb).
  • Greater than 10% cumulative risk of developing active TB disease (determined by TSTin3D.com).

Exclusion Criteria:

  • A subject will be excluded if any of the following criteria are met:
  • Presence of active TB disease
  • BMI <16
  • Cardiovascular instability (Blood pressure: Systolic >180 or <90 mm/Hg or Diastolic >100 or < 50mm/Hg; pulse <40 or >110)
  • Chest X-Ray report within last 3 months not available
  • HIV positive and currently on treatment with a regimen that has severe drug interactions with 3HP.
  • Presumed infected with INH or Rifapentine (RIF)-resistant M. tuberculosis
  • Women who are pregnant, nursing or expect to become pregnant for the duration of the study.
  • Temperature ≥38.5°C or other clinical evidence of an acute infection at screening
  • History of treatment for >14 consecutive days with a rifamycin or >30 consecutive days with isoniazid during the previous 2 years
  • Documented history of completing adequate treatment for active tuberculosis or latent M. tuberculosis infection in a HIV-seronegative person
  • History of sensitivity/intolerance to isoniazid or rifamycins
  • Serum aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) if AST was determined
  • Hemodynamic instability or medical/psychological condition precluding participation in the study as judged by the investigator
  • No access to a smartphone for personal use
  • Refuse blood draws
  • Refuse to participate in the study
  • If female of childbearing potential and on a hormonal contraception method, refuse to use an additional barrier method with the hormonal method for the duration of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Untreated Latent Tuberculosis Infection
Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
Drug: Rifapentine 600 mg orally
Once a week for 12 weeks using Video Directly Observed Therapy
Other Names:
  • Priftin
Drug: Isoniazid 900 mg orally
Once a week for 12 weeks using Video Directly Observed Therapy
Other Names:
  • INH
Drug: Pyridoxine 50 mg orally
Once a week for 12 weeks using Video Directly Observed Therapy
Other Names:
  • Vitamin B6

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients completing treatment
Time Frame: 4 months
Achieving > 90% treatment completion in patients with LTBI at > 10% cumulative individual risk of developing active TB using vDOT.
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Louis University

Investigators

  • Principal Investigator: Soumya Chatterjee, MD, St. Louis University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 30, 2019

Primary Completion (Anticipated)

January 31, 2020

Study Completion (Anticipated)

January 31, 2020

Study Registration Dates

First Submitted

December 19, 2018

First Submitted That Met QC Criteria

December 19, 2018

First Posted (Actual)

December 21, 2018

Study Record Updates

Last Update Posted (Actual)

July 1, 2019

Last Update Submitted That Met QC Criteria

June 27, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29312

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Latent Tuberculosis

Clinical Trials on Rifapentine 600 mg orally

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe